Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

J. J. Cornelissen*, J. Versluis, J. R. Passweg, W. L. J. van Putten, M. G. Manz, J. Maertens, H. B. Bverloo, P. J. M. Valk, M. van Marwijk Kooy, P. W. Wijermans, M. R. Schaafsma, B. J. Biemond, M-C Vekemans, D. A. Breems, L. F. Verdonck, M. F. Fey, M. Jongen-Lavrencic, J. J. W. M. Janssen, G. Huls, J. KuballT. Pabst, C. Graux, H. C. Schouten, A. Gratwohl, E. Vellenga, G. Ossenkoppele, B. Loewenberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

93 Citations (Web of Science)
21 Downloads (Pure)

Abstract

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n = 337) versus chemotherapy (n = 271) or autologous HSCT (autoHSCT) (n = 152) in 760 patients aged 40-60 years with AML in CR1. Patients receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy (respectively, 57 +/- 3% vs 40 +/- 3% at 5 years, P <0.001). Comparable OS was observed following alloHSCT and autoHSCT in patients with intermediate-risk AML (60 +/- 4 vs 54 +/- 5%). However, alloHSCT was associated with less relapse (hazard ratio (HR) 0.51, P <0.001) and better relapse-free survival (RFS) (HR 0.74, P = 0.029) as compared with autoHSCT in intermediate-risk AMLs. AlloHSCT was applied following myeloablative conditioning (n = 157) or reduced intensity conditioning (n = 180), resulting in less NRM, but comparable outcome with respect to OS, RFS and relapse. Collectively, these results show that alloHSCT is to be preferred over chemotherapy as PRT in patients with intermediate-and poor-risk AML aged 40-60 years, whereas autoHSCT remains a treatment option to be considered in patients with intermediate-risk AML.
Original languageEnglish
Pages (from-to)1041-1050
JournalLeukemia
Volume29
Issue number5
DOIs
Publication statusPublished - May 2015

Cite this